Literature DB >> 33228774

Comparison of methylation capture sequencing and Infinium MethylationEPIC array in peripheral blood mononuclear cells.

Chang Shu1,2, Xinyu Zhang1,2, Bradley E Aouizerat3,4, Ke Xu5,6.   

Abstract

BACKGROUND: Epigenome-wide association studies (EWAS) have been widely applied to identify methylation CpG sites associated with human disease. To date, the Infinium MethylationEPIC array (EPIC) is commonly used for high-throughput DNA methylation profiling. However, the EPIC array covers only 30% of the human methylome. Methylation Capture bisulfite sequencing (MC-seq) captures target regions of methylome and has advantages of extensive coverage in the methylome at an affordable price.
METHODS: Epigenome-wide DNA methylation in four peripheral blood mononuclear cell samples was profiled by using SureSelectXT Methyl-Seq for MC-seq and EPIC platforms separately. CpG site-based reproducibility of MC-seq was assessed with DNA sample inputs ranging in quantity of high (> 1000 ng), medium (300-1000 ng), and low (150 ng-300 ng). To compare the performance of MC-seq and the EPIC arrays, we conducted a Pearson correlation and methylation value difference at each CpG site that was detected by both MC-seq and EPIC. We compared the percentage and counts in each CpG island and gene annotation between MC-seq and the EPIC array.
RESULTS: After quality control, an average of 3,708,550 CpG sites per sample were detected by MC-seq with DNA quantity > 1000 ng. Reproducibility of DNA methylation in MC-seq-detected CpG sites was high among samples with high, medium, and low DNA inputs (r > 0.96). The EPIC array captured an average of 846,464 CpG sites per sample. Compared with the EPIC array, MC-seq detected more CpGs in coding regions and CpG islands. Among the 472,540 CpG sites captured by both platforms, methylation of a majority of CpG sites was highly correlated in the same sample (r: 0.98-0.99). However, methylation for a small proportion of CpGs (N = 235) differed significantly between the two platforms, with differences in beta values of greater than 0.5.
CONCLUSIONS: Our results show that MC-seq is an efficient and reliable platform for methylome profiling with a broader coverage of the methylome than the array-based platform. Although methylation measurements in majority of CpGs are highly correlated, a number of CpG sites show large discrepancy between the two platforms, which warrants further investigation and needs cautious interpretation.

Entities:  

Keywords:  DNA methylation; EPIC; Methylation capture sequencing; Peripheral blood mononuclear cells

Mesh:

Year:  2020        PMID: 33228774      PMCID: PMC7684759          DOI: 10.1186/s13072-020-00372-6

Source DB:  PubMed          Journal:  Epigenetics Chromatin        ISSN: 1756-8935            Impact factor:   4.954


Introduction

The rapid increase in the number of epigenome-wide association studies (EWAS) have successfully identified differentially methylated CpG sites that are associated with environmental exposures and diseases [1-6]. Such DNA methylation marks have been used as biomarkers for diagnosing, subtyping, and monitoring disease progression [7-11]. The most popular and affordable methods to profile epigenome-wide DNA methylation are array-based platforms, primarily the Illumina Human Methylation 450 K (450 K) and Infinium MethylationEPIC (EPIC) BeadChips (Illumina Inc, San Diego, CA). These arrays utilize Illumina’s beadchip technology that does not require polymerase chain reaction (PCR), but is subject to dye intensity biases between the two platforms [12]. These arrays have limited coverage of the methylome and can only detect up to 870,000 CpGs across the epigenome, leaving a large proportion of CpG sites unmeasured. Moreover, the EPIC array offers improved but still suboptimal coverage of regulatory elements [13]. Whole-genome bisulfite sequencing (WGBS) is able to capture more than 28 million CpGs, but the feasibility remains low for the population-based EWAS due to high cost and large genomic DNA input requirements to compensate for degradation during DNA bisulfite treatment. Alternatively, Methylation Capture Sequencing (MC-seq) is able to detect DNA methylation at single-nucleotide resolution utilizing a targeted next-generation sequencing approach [14]. It permits profiling of significantly more CpG sites than the EPIC array, requires less genomic DNA input than WGBS, and less expensive than WGBS, but can be susceptible to bias due to the presence of PCR duplicates. Feature-to-cost comparisons among different platforms can help understand the utilities of each platform and provide guidance for investigators in choosing a methylation profiling platform. A few studies have compared the CpG coverage, reproducibility, and performance of array-based and MC-seq platforms [15-17]. Teh et al. compared MC-seq and the 450 K array in seven DNA samples extracted from saliva [15]. A recent study compared the EPIC array and TruSeq targeted bisulfite sequencing in four cord blood DNA samples [17]. However, no comparisons of MC-seq and array-based methylome profiling of peripheral blood mononuclear cells (PBMCs) has been reported. Here, we profiled the DNA methylome in PBMCs using the Agilent SureSelect Methyl-Seq platform and compared the results to the EPIC array in DNA samples extracted from PBMCs.

Methods

Methylation capture sequencing (MC-seq)

DNA samples description

DNA was extracted from de-identified PBMCs collected from four individuals. Genomic DNA quality was determined by estimating the A260/A280 and A260/A230 ratios by spectrophotometry and concentration by fluorometry. DNA integrity and fragment size were confirmed using a microfluidic chip run on an Agilent Bioanalyzer. To assess the reproducibility of MC-seq by DNA quantity, DNA samples from each participant were profiled in triplicate times with high (> 1000 ng), medium (300–1000 ng), and low (150–300 ng) DNA input. In total, 12 DNA samples were measured by MC-seq. Bisulfate conversion was conducted for each DNA sample as described below.

Methyl-seq target enrichment library prep

Indexed paired-end whole-genome sequencing libraries were prepared using the SureSelect XT Methyl-Seq kit (Agilent, part#G9651B). Genomic DNA was sheared to a fragment length of 150–200 bp using focused acoustic energy delivered by the Covaris E220 system (Covaris, part#500003). Fragmented sample size distribution was determined using the Caliper LabChip GX system (PerkinElmer, Part#122000). Fragmented DNA ends were repaired with T4 DNA Polymerase and Polynucleotide Kinase and “A” base was added using Klenow fragment in a single reaction followed by AMPure XP bead-based purification (Beckman Coulter, part#A63882). The methylated adapters were ligated using T4 DNA ligase followed by AMPure XP bead purification. Quality and quantity of adapter-ligated DNA were assessed using the Caliper LabChip GX system. Samples yielding > 350 ng were enriched for targeted methylation sites by using the custom SureSelect Methyl-Seq Capture Library. Hybridization was performed at 65 °C for 16 h using a C1000 Thermal Cycler (BIO-RAD, part# 1851197). Once the enrichment was completed, the samples were mixed with streptavidin-coated beads (Thermo Fisher Scientific, part#65602) and washed with a series of buffers to remove non-specific bound DNA fragments. DNA fragments were eluted from beads with 0.1 M NaOH. Unmethylated C residues of enriched DNA were modified by bisulfite conversion using the EZ DNA Methylation-Gold Kit (Zymo Research, part#D5005). The SureSelect enriched, bisulfite-converted libraries were PCR amplified using custom-made indexed primers (IDT, Coralville, Iowa). Dual-indexed libraries were quantified by quantitative polymerase chain reaction (qPCR) using the Library Quantification Kit (KAPA Biosystems, Part#KK4854) and inserts size distribution was assessed using the Caliper LabChip GX system. Samples with a yield of ≥ 2 ng/μl were proceeded to sequencing.

Flow cell preparation and sequencing

Sample concentrations were normalized to 10 nM and loaded onto an Illumina NovaSeq flow cell at a concentration that yields 40 million passing filter clusters per sample. Samples were sequenced using 100 bp paired-end sequencing on an Illumina HiSeq NovaSeq according to Illumina standard protocol. The 10 bp dual index was read during additional sequencing reads that automatically follows the completion of the first read. Data generated during sequencing runs were simultaneously transferred to the Yale Center for Genome Analysis high-performance computing cluster. A positive control (prepared bacteriophage Phi X library) provided by Illumina was spiked into every lane at a concentration of 0.3% to monitor sequencing quality in real time.

Preprocessing and quality control

Signal intensities were converted to individual base calls during a run using the system’s Real Time Analysis (RTA) software. Sample de-multiplexing and alignment to the human genome was performed using Illumina’s CASAVA 1.8.2 software suite. The sample error rate was required to be less than 1% and the distribution of reads per sample in a lane was required to be within reasonable tolerance. Quality control (QC) on MC-seq was conducted following standard procedure as previously described [18]. Quality of sequence data was examined by using FastQC (ver. 0.11.8). Adapter sequences and fragments at 5′ and 3′ (phred score < 20) with poor quality were removed by Trim_galore (ver. 0.6.3_dev). We used Bismark pipelines (ver. v0.22.1_dev) to align the reads to the bisulfite human genome (hg19) with default parameters [19]. Quality-trimmed paired-end reads were transformed into a bisulfite converted forward strand version (C → T conversion) or into a bisulfite-treated reverse strand (G → A conversion of the forward strand). Duplicated reads were removed from the Bismark mapping output by deduplicate_bismark and CpG, CHG, and CHH (where H = A, T, or C) were extracted by bismark_methylation_extractor. All CpG sites were grouped by sequencing coverage, also known as read depth. The groups with coverage of 1× to 100× were used to test the relationship between coverage and number of CpG sites. Only the CpG sites with coverage > 10× depth were used for final comparisons to ensure MC-seq data quality. Genes were annotated using Homer annotatePeaks.pl, including intergenic, 5′UTR, promoter, exon, intron, 3′UTR, transcription start site (TTS), and non-coding categories. CpG island, shore, shelf, and open sea annotation were defined by locally developed bash and R scripts based on genomic coordinates (hg19) of CpG islands from the UCSC genome browser. CpG shores was defined as up to 2 kb from CpG islands and CpG shelf was defined as up to 2 kb from a CpG shore.

Assessment of reproducibility

We assessed CpG- and participant-based reproducibility for MC-seq among 12 samples with DNA quantity of high, medium, and low input in two ways. First, CpG-based reproducibility was assessed by calculating Pearson correlations using the CpG sites in common of the samples from the same participant with different input DNA quantities. Scatterplots were rendered showing 10,000 randomly selected common CpG sites comparing samples with high and medium, high and low, and medium and low DNA inputs. Second, participant-based reproducibility was assessed by comparing methylation profiles among pairs of participants using the samples with high DNA inputs, by calculating Pearson correlations of common CpG sites.

EPIC array data preprocessing

The Infinium MethylationEPIC array (Illumina, San Diego, CA, USA) was used to measure PBMC DNA methylation profiles from the same four participants. These four samples with DNA input of 1000 ng were preprocessed using standard procedures as previously described [20]. Briefly, the predicted sex based on methylome was consistent with self-reported sex for all samples. All samples had a call rate greater than 0.15. A total of 19,090 CpG sites on X chromosomes and 537 CpG sites on Y chromosomes were filtered. A total of 846,464 CpG sites passed quality control.

Comparison of methylation at each CpG site between MC-seq and EPIC array

The overall distribution of gene annotation in relation to CpG island and genetic region between MC-seq and EPIC array data from the four participants was compared. Common CpG sites between MC-seq and EPIC array assays were defined according to genomic coordinates. Pearson correlation and the absolute beta-difference value (Δβ) were calculated among common CpG sites between MC-seq methylation percentage values and EPIC methylation beta values by using R (ver. 3.5.1). If median Δβ of the common CpG site between two platforms was > 0.1, it was defined as a discordant CpG pair; otherwise, the CpG site was defined as a concordant CpG pair. The density plot of Δβ and a Manhattan plot showing the distribution of Δβ across epigenome were illustrated. Scatterplots were rendered showing the correlation of β values from 10,000 randomly selected CpG sites measured by both MC-seq and EPIC array.

Results

MC-seq overview and reproducibility

In MC-seq, all sequences were efficiently mapped to the reference genome with greater than 89% mapping efficiency. Interestingly, the number of non-CpG sites was significantly greater than the number of CpG sites. Among all detected methylation sites by MC-seq, 11% were CpG sites, 65% were CHH sites, and 24% were CHG sites (Fig. 1a).
Fig. 1

Methylation Capture Sequencing (MC-seq). a Distribution of methylation sequence context (CpG, CHH, CHG); b Coverage depth versus a number of detected CpG sites; c Detected CpG sites in low, medium, and high DNA inputs for four participants using MC-seq with minimum coverage ≥ 10×; d Scatterplots comparing 10,000 randomly selected common CpG sites among samples with high, medium, and low DNA input quantities and their Pearson correlations

Methylation Capture Sequencing (MC-seq). a Distribution of methylation sequence context (CpG, CHH, CHG); b Coverage depth versus a number of detected CpG sites; c Detected CpG sites in low, medium, and high DNA inputs for four participants using MC-seq with minimum coverage ≥ 10×; d Scatterplots comparing 10,000 randomly selected common CpG sites among samples with high, medium, and low DNA input quantities and their Pearson correlations Figure 1b shows the relationship of the number of detected CpG sites and depth of sequence coverage by MC-seq in one sample. The depth of read at which the majority of sites were sequenced was estimated to be approximately 10× coverage, observed as the inflection point of the distribution of Fig. 1b. An increase of depth only slightly increased the capture of CpG sites and the inflection point is on 10× coverage, consistent with previous literature [15, 17]. Thus, the number of CpG sites with coverage ≥ 10× from MC-seq was used in subsequent analyses. After quality control filtering, MC-seq captured an average of 2,878,207 methylation CpG sites with coverage ≥ 10× among the 12 DNA samples, with an average of 3,708,550 CpG sites among samples with high DNA input (> 1000 ng), an average of 3,046,172 CpG sites among samples with medium DNA input (300–1000 ng), and an average of 1,879,898 CpG sites among samples with low DNA input (150–300 ng) (Fig. 1c and Table 1). Despite the fact that the detected number of CpG sites varied depending on DNA input quantity, CpG-based correlation among the common CpG sites between samples with high and medium, high and low DNA input quantities exceeded r > 0.95. Correlations of common CpG sites between medium and low DNA inputs were also high with r in 0.92–0.94 (Table 2). Figure 1d shows the scatterplot of 10,000 randomly selected common CpGs between samples with high and medium, high and low, and medium and low DNA input quantities. Pair-wise participant-based correlations were high as r > 0.98 among common CpG sites (Table 3). Overall, MC-seq exhibited good reproducibility. The methylation profile generating in high DNA input from each participant was used for subsequent analyses.
Table 1

Detected CpG number by DNA amount in MC-seq with coverage ≥ 10×

DNA amountParticipant IDCpG numberAverage CpG number
LowS11,774,9401,879,898
S21,831,086
S32,154,732
S41,758,834
MediumS12,768,4563,046,172
S23,338,200
S33,119,259
S42,958,772
HighS13,406,8793,708,550
S23,642,776
S33,722,552
S44,061,994
Total average2,878,207
Table 2

Comparison of MC-seq between samples with high, medium, and low DNA input amount

Participant IDDNA amount
HighMediumCommon CpGPearson correlation
S13,406,8792,768,4562,747,8440.984
S23,642,7763,338,2003,283,2960.984
S33,722,5523,119,2593,101,9380.977
S44,061,9942,958,7722,957,2390.979
Table 3

Overlap of detected CpG across samples with high DNA input amount by MC-seq

Participant ID 1Participant ID 2Common CpGPearson R
S1S23,336,0370.980
S1S33,350,3140.976
S1S43,394,9700.982
S2S33,519,7720.978
S2S43,613,7530.982
S3S43,676,4060.978
Detected CpG number by DNA amount in MC-seq with coverage ≥ 10× Comparison of MC-seq between samples with high, medium, and low DNA input amount Overlap of detected CpG across samples with high DNA input amount by MC-seq

Distribution of methylome regions by MC-seq and EPIC

We compared genome-wide DNA methylation captured by MC-seq and by EPIC array in the four high DNA input samples. An average of 3,708,550 CpG sites were detected by MC-seq and 846,464 CpG sites by EPIC array. Overall, MC-seq detected 11.5 times more CpG sites in exons and 10.2 times more CpG sites in 5′ UTR region compared to the EPIC array, and 4.8 to 8.9 times more CpG site in other categories of genomic regions by MC-seq compared to EPIC array. However, the proportion of CpGs out of all CpGs successfully measured that map to gene regions in MC-seq as compared to the EPIC array did not significantly differ between these two platforms. For example, the proportion of CpG sites in transcription termination site (TTS) regions was similar between two platforms. MC-seq showed slightly greater proportions of CpG sites in 5′UTR and exon regions, while the EPIC array detected a greater proportion of CpG sites in promoter regions (Fig. 2a). In terms of CpG sites in relation to CpG islands including open seas, shelves, and shores, MC-seq detected 10.9 times more CpG sites located on CpG islands and 5.4–6.2 times more on other regions compared with the EPIC array. The proportion of CpG islands detected by MC-seq was greater than by the EPIC array (42% versus 29%), while the EPIC array detected a modestly higher percentage of CpG sites located in open seas than the MC-seq (39% versus 31%) (Fig. 2b).
Fig. 2

Comparison of CpG proportion in epigenomic regions between MC-seq and EPIC. a Distribution of genomic regions (intergenic, promoter, 5′UTR, exon, intron, non-coding, 3′UTR, transcription termination site (TTS), and non-coding). b Distribution of CpG position relative to CpG islands (CpG island, shore, shelf, and open sea)

Comparison of CpG proportion in epigenomic regions between MC-seq and EPIC. a Distribution of genomic regions (intergenic, promoter, 5′UTR, exon, intron, non-coding, 3′UTR, transcription termination site (TTS), and non-coding). b Distribution of CpG position relative to CpG islands (CpG island, shore, shelf, and open sea)

Comparison of Common CpG sites Measured by MC-seq and EPIC

A total of 472,540 CpG sites were measured by both platforms. Overall, the correlations of these shared CpG sites was high, ranging from r = 0.983 to 0.985 across the four samples (Fig. 3a). Figure 3b presents the distribution of the absolute difference of methylation β values between MC-seq and EPIC. A small proportion of CpG sites (1.4%) were discordant (i.e., Δβ > 0.1), while 98.6% of CpG sites were concordant (i.e., Δβ < 0.1). Figure 3a presents the concordant (blue) and discordant CpG sites (green) between MC-seq and EPIC for participant S1 (Fig. 3a). The 60,753 discordant CpG sites appeared to be randomly distributed across the epigenome (Additional file 1: Figure S1). Among the discordant CpG sites, we identified 239 CpG sites with highly discrepant methylation (i.e., Δβ > 0.5) (Table 4). Addition file 2: Table S1 presents top 100 discordant CpG sites with medium discrepant methylation (Dβ = 0.1 ~ 0.4)Additional file 3: Figure S2 shows that participants S2, S3, and S4 have similar distribution of concordant and discordant plots as participant S1.
Fig. 3

Comparing methylation values among common CpG sites between MC-seq and EPIC. a Correlation of methylation values measured by MC-seq and EPIC array among common CpG sites in participant S1. Blue dots represent concordant CpGs with Δβ < 0.1 between the two platforms and green dots represent discordant quality with Δβ ≥ 0.1; b The distribution of median Δβ in common CpG sites between MC-seq and EPIC array. The red dotted line represents Δβ = 0.1 as a cutoff for concordant CpG site between two platforms. c The density plot of methylation values among common CpG sites profiled by MC-seq and EPIC array in participant S1

Table 4

Discordant CpG sites between MC-seq and EPIC (difference>0.5)

ProbeChrPositionGeneMC-seq medianEPIC medianMedian Difference between MC-seq and EPICRefgene groupRelation to CpG island
cg0915651991033615720.0090.9600.95S_Shore
cg18176117996097296C9orf1290.0000.9320.93BodyN_Shore
cg14268958101334530660.0000.8990.89S_Shelf
cg1057628010124133822PLEKHA10.0720.9480.88TSS1500N_Shore
cg010054863132460060.0470.8860.84Island
cg23433318196675420.0070.8660.84Island
cg107661727274984790.9890.1470.82
cg11812439468928706LOC550113;SYT14P1;TMPRSS11F0.9730.1550.82Body; Body; Body
cg239504735154393265KIF4B; KIF4B0.9920.1740.821stExon; 5’UTR
cg0025984984183880CSMD10.0000.8210.82Body
cg2398115011611110901.0000.2170.78Island
cg09698465121330001780.9060.0800.78Island
cg204509771110529463MTRNR2L8; MTRNR2L80.9640.1890.773’UTR; 1stExon
cg01053463126186087C1orf1350.0210.7570.76TSS1500Island
cg124998272202004893CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR; CFLAR0.9710.2150.76TSS200; Body; Body; Body; Body; Body; Body; Body; Body
cg031337772170361364BBS51.0000.2440.753’UTR
cg1904070217220238330.9690.2300.75
cg2167587111698133970.2170.9600.74Island
cg042404933148414664AGTR1; AGTR1; AGTR1; AGTR10.9790.2580.72TSS1500; TSS1500; TSS1500; TSS1500N_Shore
cg1688942710127584375FANK10.0360.7590.71TSS1500Island
cg259165051832820654ZNF397; ZNF3970.0000.7110.71TSS1500; TSS1500N_Shore
cg135250261718061071MYO15A1.0000.2900.71Body
cg0782543341215099CTBP1; CTBP10.0000.7160.71Body; BodyN_Shelf
cg038466412109746751LOC100287216; SH3RF30.2390.9520.71TSS200; BodyIsland
cg19188207210340837C2orf481.0000.2900.71Body
cg114955441773402155GRB2; GRB20.7530.0490.70TSS1500; TSS1500S_Shore
cg06931905842036940PLAT; PLAT0.8960.1970.70Body; Body
cg0334890215696030.8690.1680.70
cg271209346129480619LAMA2; LAMA20.9790.2970.69Body; Body
cg07576219155012408ACOT11; ACOT110.9270.2500.69TSS1500; TSS1500S_Shelf
cg084002465156570642MED7; MED70.1530.8700.68TSS1500; TSS1500S_Shore
cg276261418103876469AZIN1; AZIN10.0000.6820.68TSS200; TSS200Island
cg266884722203638928ICA1L0.9840.3030.683’UTRIsland
cg2610118310659307860.9570.2790.68Island
cg270900071328519388ATP5EP20.9850.3210.67Body
cg118960121953696753ZNF6650.0480.7000.67TSS200S_Shore
cg0260601812106582810.9790.3230.66
cg004381644100870480H2AFZ; LOC2568800.0040.6500.65Body; TSS1500Island
cg2116430091360984950.0000.6440.64N_Shelf
cg1589107610659306180.9710.3280.64Island
cg05948389516419240.0140.6600.64N_Shelf
cg1050796510102107251SCD; SCD0.0110.6420.645’UTR; 1stExonIsland
cg216623261114521493COPB1; COPB1; COPB10.6430.0120.63TSS200; TSS200; TSS200
cg09646578850193630.3100.9340.63
cg247179642061477008DPH3B; DPH3B; TCFL50.9860.3560.631stExon; 5’UTR; Body
cg074379198142234483SLC45A40.9570.3130.63BodyN_Shore
cg0110540322407233040.0500.8900.63
cg204821437643408040.9820.3460.63
cg1118745222496986120.0170.6530.63Island
cg24504954361237217FHIT; FHIT0.0170.6490.62TSS200; TSS200Island
cg274343511114521491COPB1; COPB1; COPB10.6390.0160.62TSS200; TSS200; TSS200
cg1586407421209740420.9760.3540.62
cg009135211289893799WDR51B0.9770.3390.62Body
cg2753456715685360.8340.2620.62
cg2451513617490248340.9490.3280.62S_Shelf
cg01417615152456419RAB3B0.6290.0150.61TSS200Island
cg002363021269004867RAP1B; RAP1B0.0000.6120.615’UTR; 5’UTRIsland
cg107476032229197018XBP1; XBP10.0220.6270.61TSS1500; TSS1500S_Shore
cg035944471203597441.0000.3580.61
cg2304527741905878080.2990.9100.61
cg022188091629973300TMEM219; TMEM2190.0200.6120.61TSS200; TSS200Island
cg0564649110135379754SYCE1; SYCE1; SYCE10.9880.3820.60TSS1500; 5’UTR; TSS1500Island
cg075961742055926107RAE1; RAE10.0140.6130.60TSS1500; TSS200N_Shore
cg03543448164384967GLIS20.9270.3150.60Body
cg25793197531923469PDZD20.9760.3790.60Body
cg213922292161223778RBMS1; RBMS11.0000.3840.60Body; Body
cg056073201253342553KRT18; KRT180.0640.6510.60TSS200; TSS1500N_Shore
cg13896861994878241SPTLC1; SPTLC10.1170.7110.60TSS1500; TSS1500S_Shore
cg0306490041905661410.3230.9210.60N_Shore
cg161998593752636850.8610.2760.60
cg150068431205720633NUCKS10.8800.2600.60TSS1500S_Shore
cg02498218426361371RBPJ; RBPJ; RBPJ; RBPJ0.9790.3880.59Body; Body; 5’UTR; BodyIsland
cg0711671215968879590.0910.6810.59Island
cg116433062034204831SPAG40.0380.6300.59BodyS_Shore
cg085685617428344980.9810.3920.59
cg066695986127622363ECHDC1; ECHDC1; ECHDC1; ECHDC1; ECHDC10.9840.3510.593’UTR; 3’UTR; Body; Body; Body
cg228054313113955600ZNF800.9830.4090.591stExon
cg24636332174437925SPNS20.3010.9390.59BodyN_Shore
cg059241911535279830ZNF7700.0080.6050.595’UTRN_Shore
cg144021941423398944PRMT5; PRMT5; PRMT5; PRMT5; PRMT5; PRMT5; LOC1019269330.0280.5920.58TSS200; TSS200; TSS200; TSS200; TSS200; TSS200; BodyS_Shore
cg017375324190862170FRG10.0000.5840.581stExonIsland
cg257440171552819324MYO5A; MYO5A0.9570.3790.58Body;BodyN_Shore
cg034321511589745000ABHD2; ABHD20.9480.3600.583’UTR; 3’UTR
cg2719669510134571377INPP5A1.0000.4200.58Body
cg2757135110176193640.9860.4070.58
cg0277580421209740800.9770.4010.58
cg16461530101347982640.6640.1060.58
cg1265477010524876930.9620.3850.58
cg161128801201123745TMEM90.0030.5790.58TSS200Island
cg2064142381253150650.9110.3380.57S_Shore
cg232486151020057090.9050.3130.57
cg255502797532549830.9650.3810.57Island
cg0107025015696870.8430.2710.57
cg0697757541394819900.9530.3760.57Island
cg145116449150550210.9770.3990.57
cg08947542835383200UNC5D0.8790.3090.57Body
cg102580632217363243RPL37A0.0430.6130.57TSS1500N_Shore
cg2420972318129131330.9730.3990.57S_Shore
cg02265379587898506LOC6453230.9710.3840.57BodyIsland
cg1892560171587527150.0060.5740.57Island
cg0140607511587311040.8850.3090.57N_Shore
cg135452971254404315HOXC80.2290.7910.57BodyS_Shore
cg0903653110969915050.9680.4020.57
cg256492839140714075EHMT10.3820.9500.57BodyIsland
cg06204030177792051CHD3; CHD3; CHD30.7610.1410.57TSS200; TSS200; BodyS_Shelf
cg1862732819621561POLRMT0.9800.4110.56BodyIsland
cg13085681848920761UBE2V20.0090.5760.56TSS1500N_Shore
cg00999469625107287CMAHP0.0430.9310.56Body
cg209600399130213605LRSAM1; RPL12; LRSAM1; LRSAM1; LRSAM1; RPL120.0200.5820.56TSS1500; 1stExon; TSS200; TSS200; TSS200; 5’UTRIsland
cg044008412208988863CRYGD0.2150.7640.56BodyIsland
cg124762981958426697ZNF4170.9770.4070.56BodyN_Shore
cg239974021914275669LPHN1; LPHN10.9720.4420.56Body; BodyS_Shore
cg169353705154393281KIF4B; KIF4B0.9810.4140.561stExon; 5′UTR
cg042221591204981786NFASC; NFASC; NFASC; NFASC0.6300.0730.56Body; Body; Body; Body
cg063962378120779442TAF20.9850.4300.56Body
cg065995436165749446PDE10A;PDE10A0.8570.3320.56Body;BodyS_Shore
cg115668321088659593BMPR1A0.1450.6930.55Body
cg203340101541047916RMDN3; RMDN30.0200.5700.55TSS1500; TSS1500S_Shore
cg18245781536596970.2830.8520.55
cg03761810210264850RRM2; RRM20.0180.5670.55Body; BodyS_Shore
cg021223723149657597RNF13; RNF131.0000.4390.55Body; Body
cg06753227189475508RALBP10.0000.5530.55TSS200Island
cg141318341345914250LOC100190939; TPT10.0400.5940.55TSS1500; BodyN_Shore
cg255831805177614382GMCL1L1.0000.4510.55BodyIsland
cg09112623633756905LEMD2; LEMD20.5680.0190.555’UTR; 1stExonIsland
cg117594774190861959FRG10.0000.5480.55TSS200Island
cg127967551451132292SAV10.9320.3830.55BodyN_Shelf
cg19693446141021441920.9580.4070.55
cg25187648349395165GPX1; GPX1; GPX10.0180.5680.55Body; 3’UTR; 1stExonIsland
cg203918336167116208RPS6KA20.9640.4310.55Body
cg09705232697611802MIR548H3; C6orf1670.9740.4280.55Body; Body
cg046434371214518655ATF7IP; ATF7IP0.0000.5610.551stExon; 5’UTRIsland
cg175580621345965415LOC1001909391.0000.4560.54BodyIsland
cg2682584841905661750.3500.8990.54N_Shore
cg139431419932058620.8460.2960.54
cg269517051956612697ZNF7870.0000.5420.54BodyIsland
cg246540941160340832NHLH10.9640.4330.54BodyIsland
cg0299635514818793750.9090.3640.54
cg1191481212569047921.0000.4590.54
cg2489597719358617960.9900.4500.54
cg116376826147124984LOC729176; C6orf1030.8670.3000.54TSS200; Body
cg070896331473396378DCAF4; DCAF4; DCAF4; DCAF4; DCAF41.0000.4500.545’UTR; 5’UTR; 5’UTR; 5’UTR; 5’UTRS_Shelf
cg2036041647246127SORCS20.0180.6590.54Body
cg256279201739992620NT5C3B; NT5C3B; NT5C3B; KLHL100.0160.5520.54TSS200; TSS200; TSS200; TSS1500Island
cg24000259555488291ANKRD550.9610.4110.54Body
cg091384371164527189PYGM; PYGM0.9930.4450.541stExon; 1stExon
cg0267363611096470560.9760.4370.54S_Shelf
cg18740872539220260FYB; FYB1.0000.4660.53TSS1500; TSS1500
cg143542927633536060.9600.4260.53
cg17704839199939038UBL5; UBL50.0140.5420.53Body; BodyS_Shore
cg059713737157498604PTPRN2; PTPRN2; PTPRN21.0000.4670.53Body; Body; BodyS_Shelf
cg05291429171494566SLC43A20.4020.9690.53BodyS_Shelf
cg088413423156528470PA2G4P40.9760.4440.53Body
cg040966976370128670.9830.4510.53Island
cg268789951168106731GPR1610.0520.5700.53TSS1500S_Shore
cg2403152420198046060.9900.4680.53
cg19311470439460490RPL9; RPL9; LIAS; LIAS0.0040.5290.53TSS1500; 5’UTR; TSS200; TSS200Island
cg0218148251789426850.9560.4490.53
cg053469021947910374MEIS3; MEIS30.0680.5930.53Body; BodyIsland
cg164707721082033040.9710.4450.53
cg101150221275279420.9740.4640.53Island
cg272317176263193770.9050.3860.53
cg09451549198386408RPS28; NDUFA7; RPS280.0000.5270.535’UTR; TSS200; 1stExonIsland
cg07628841227851430GPN1; CCDC121; GPN1; GPN1; CCDC121; CCDC121; GPN1; GPN10.0100.5360.53TSS200; 1stExon; TSS200; TSS1500; 5’UTR; 1stExon; TSS200; TSS1500
cg038160811029577743LYZL10.8630.3010.52TSS1500
cg007620032145393541AGPAT3; AGPAT30.3830.8920.52Body; BodyIsland
cg194669227130138026MEST; MEST; MEST; MEST; MEST; MEST1.0000.4760.52Body; Body; Body; Body; Body; Body
cg077121651780899280TBCD0.4400.9590.52BodyIsland
cg0119995213255914860.9840.4560.52N_Shore
cg113748343752636910.9500.4280.52
cg0297449111162280SDF4; SDF40.4030.9640.52Body; BodyIsland
cg105558531335166270.9290.4070.52Island
cg2121660622072757040.9850.4640.52
cg17711541626124704HIST1H2AC; HIST1H2BC0.0070.5290.521stExon; TSS1500Island
cg06412823722541074STEAP1B; STEAP1B0.1960.7390.52TSS1500; TSS1500S_Shore
cg0305434311502382141.0000.4630.52Island
cg057666051193848270.4230.9380.52
cg0768421510132976057TCERG1L0.1810.9230.52Body
cg27193858641169120TREML20.1810.6910.52TSS200
cg009643211615083956PDXDC10.9060.3860.52BodyIsland
cg253945721156457777OR8U80.9490.4290.52Body
cg1066796931491819410.9670.4580.52
cg18394854584578180.2120.7320.52Island
cg0574122510133917303JAKMIP30.9060.3700.52TSS1500
cg060267691220704492PDE3A0.9930.4730.52BodyN_Shore
cg09032630627831956HIST1H2AL0.8020.3110.52TSS1500N_Shore
cg166264802225575426KIAA16710.9500.4220.52BodyIsland
cg245347311736888147CISD30.9690.4570.52BodyS_Shore
cg1620225914104625420KIF26A0.0580.9620.52BodyIsland
cg25325592814395350.4080.9230.52N_Shore
cg003910253100427239TFG; TFG1.0000.4770.52TSS1500; TSS1500N_Shore
cg2514903717397362130.8200.4540.52
cg19120749111431650BRSK2; BRSK2; BRSK2; BRSK2; BRSK2; BRSK20.4680.9830.52TSS1500; TSS200; Body; Body; Body; BodyIsland
cg242706241095721318PIPSL0.9470.4210.52Body
cg1634658810242978ZMYND11; ZMYND11; ZMYND110.9700.4590.51Body; Body; Body
cg027503221583673816C15orf40; C15orf40; C15orf40; C15orf40; C15orf400.9660.4510.51Body; 3’UTR; Body; Body; Body
cg04363536349466872NICN10.0000.5150.51TSS200S_Shore
cg178833711913592251.0000.4800.51Island
cg250188321564471LOC1019286260.6020.0880.51TSS200
cg168387294439010320.9030.3940.51
cg232222471747302219PHOSPHO1; PHOSPHO10.0090.5310.51Body;BodyIsland
cg194965661948249018GLTSCR20.0090.5350.511stExonIsland
cg03165426730726958CRHR2; CRHR20.4290.9420.51Body; 5’UTR
cg1960049421069595250.9680.4550.51Island
cg108548071779479308ACTG10.0040.5220.51BodyIsland
cg2069909711111957680TIMM8B; TIMM8B; SDHD0.0090.5240.51TSS200; TSS200; 1stExonIsland
cg228197671011866910C10orf470.9580.4400.515’UTRS_Shore
cg202542518144557206ZC3H30.9930.4500.51Body
cg00590830132385224PTP4A2; PTP4A2; PTP4A2; PTP4A2; PTP4A20.9710.4370.511stExon; 1stExon; 5’UTR; 5’UTR; 5’UTR
cg03877767211680057GREB1; GREB10.1720.6830.515’UTR; TSS200
cg0048752615908183840.9560.4440.51Island
cg175013842217364031RPL37A0.0170.5210.51BodyS_Shore
cg176464186166911767RPS6KA2; RPS6KA20.9870.4680.51Body; Body
cg067574055140789450PCDHGA4; PCDHGA9; PCDHGA1; PCDHGB1; PCDHGB6; PCDHGB6; PCDHGB3; PCDHGA6; PCDHGA8; PCDHGA5; PCDHGB4; PCDHGA3; PCDHGA2; PCDHGB2; PCDHGA7; PCDHGB50.1080.6070.51Body; Body; Body; Body; 1stExon; 1stExon; Body; Body; Body; Body; Body; Body; Body; Body; Body; BodyIsland
cg1344859682031599MYOM20.3810.8870.51Body
cg1671116511111957658TIMM8B; TIMM8B; SDHD0.0170.5220.51TSS200; TSS200; 1stExonIsland
cg1678664043485263DOK7; DOK70.4470.9540.51Body; BodyN_Shore
cg0763893810131348599MGMT0.9860.4920.51Body
cg054077108143329409TSNARE10.9600.4510.51BodyN_Shelf
cg0786999431740951900.9880.4820.51Island
cg0745540614210775270.0170.5230.51N_Shore
cg045768471712623611MYOCD; MYOCD; MYOCD; MYOCD0.9580.4470.51Body; 5’UTR; Body; 1stExon
cg1569985318576847470.9760.4670.51
cg112312408824346381.0000.4820.51Island
cg061579244942005TMEM1750.4510.9570.51BodyS_Shore
cg236791414165118930MARCH1; ANP32C0.9460.4450.515’UTR; TSS200
cg03053358171029917ABR; ABR0.4460.9640.51Body; 5’UTRS_Shore
cg1370589491383053380.9780.4950.51S_Shore
cg185127801776117734TMC6; TMC60.0330.5290.50Body; Body
cg0630794016466608180.9860.4870.50
cg15541008595297508ELL2; ELL20.0000.5160.501stExon; 5’UTRS_Shore
cg199696241395954210ABCC4; ABCC4; ABCC4; ABCC40.0110.5070.50TSS1500; TSS1500; TSS1500; TSS1500Island
cg01758870723719630C7orf46; C7orf46; C7orf460.0280.5450.50TSS200;TSS200;TSS200Island
cg0832320115101835348SNRPA10.0000.5030.501stExonIsland
cg218639981119770288NAV2; NAV2; NAV20.4390.9050.50Body; Body; Body
cg114718028475290150.3480.8820.50Island
cg2228193521629341110.9820.4810.50S_Shelf
cg060325401543941563CATSPER2; CATSPER2; CATSPER21.0000.5000.50TSS1500; TSS1500; TSS1500Island
cg1876187815684750.8930.4010.50
Comparing methylation values among common CpG sites between MC-seq and EPIC. a Correlation of methylation values measured by MC-seq and EPIC array among common CpG sites in participant S1. Blue dots represent concordant CpGs with Δβ < 0.1 between the two platforms and green dots represent discordant quality with Δβ ≥ 0.1; b The distribution of median Δβ in common CpG sites between MC-seq and EPIC array. The red dotted line represents Δβ = 0.1 as a cutoff for concordant CpG site between two platforms. c The density plot of methylation values among common CpG sites profiled by MC-seq and EPIC array in participant S1 Density plots of methylation β showed bimodal distribution using both the MC-seq and the EPIC array platforms (Fig. 3c). Density of methylated CpG sites was slightly higher than the density of unmethylated CpG sites on both platforms. However, the two peaks in the EPIC array density plot were closer than the two peaks in the MC-seq density plot (Fig. 3c), indicating that MC-seq captures a higher dynamic range (i.e., more methylated and unmethylated) of CpG sites than the EPIC array. Additional file 4: Figure S3 shows that participants S2, S3, and S4 have similar density plots.

Discussion

We profiled the same PBMC samples using the MC-seq and EPIC array platforms and compared their performance. Our results show that the Agilent SureSelect Methyl-Seq targeted enrichment platform produced high-quality DNA methylation sequencing data at single base-pair resolution. MC-seq can reliably detect CpG sites with DNA input quantities as low as 300 ng. Overall, MC-seq detected 3–4 times more CpG sites than the EPIC array; however, the proportion of CpG sites mapped on functional genomic regions was similar between the two platforms. Methylation at a majority of CpG sites between the two platforms was highly correlated, while methylation at a low percentage of CpG sites differed significantly between the two platforms. Specifically, we found that methylation at 239 CpG sites differed significantly between the two platforms with absolute Δβ values greater than 0.5, which suggests that these CpG sites should be interpreted with caution in EWAS studies. Our results show that MC-seq produces highly reliable CpG site methylation estimates across the genome. The observed CpG-based reproducibility is high, suggesting that technical variation on CpG calls is low. Inter-personal methylation variation is important for EWAS analysis. We found that our participant-based methylation on common CpG sites across four participants is also highly correlated, which further demonstrates the high reproducibility of this platform. One disadvantage of sequencing-based approaches is the requirement for a larger quantity of input DNA than array-based approaches for methylation profiling. The recommended input DNA for Agilent SureSelect platform is 1ug, while input DNA quantity for EPIC array can be as low as 250 ng. Input DNA quantity is one important consideration influencing study design and methylation assay platform selection for population-based EWAS. Agilent has reported that DNA quantity can be as low as 250 ng for SureSelect sequencing [14]. To examine whether DNA quantity impacts the performance of MC-seq and to test whether low input DNA quantity also produces reliable CpG detection, we compared the capacity of CpG site detection across three different DNA input quantities. We found that medium DNA input quantity (i.e., 300 ng to 1000 ng) reliably detected CpG sites is comparable to the number of CpG sites captured by high DNA input quantity (i.e., greater than 1000 ng). Low DNA input quantity (i.e., less than 300 ng) detected the lowest number of CpG sites compared with high and medium DNA input quantity. For samples with low DNA input quantity, additional PCR cycles are needed to ensure post-capture library yield that results in extensive duplicate reads. In the four low DNA input samples, the duplicate rate exceeds 80%. Thus, removing duplicate reads is an important step in the QC process for MC-seq. We found that the number of CpG sites in low DNA input samples without duplicated reads still is significantly higher than the number of CpG sites detected by the EPIC array. Consistent with previous reports, we found that methylation at the majority of CpG sites measured by both approaches (> 98%) is highly consistent between MC-seq and array-based methods. However, we identified 1.4% of CpG sites with discrepancies in CpG methylation that exceeds 10%. More importantly, 239 out of 60,753 discordant CpG sites had methylation differences exceeding 50%. These CpG sites are located on 159 gene regions (Table 4). Some of these genes have been previously reported to be associated with diseases. For example, SLC45A4 was reported to harbor an epigenetic marker for adiposity [21]. The methylation β differs on the CpG site of this gene by as much as 0.63 between the two platforms. We have also identified those CpG sites that showed less but still apparent discrepancy between the two assay platforms (i.e., absolute difference of beta values between 0.1 and 0.5). The top 100 CpG sites discrepant in a range of 0.1–0.4 between two platforms are presented in Table S2 to allow investigators to consider this potential source of bias in EWAS findings. The discrepancy might be due to bias in the performance of the beadchip assay at these positions, sequence context-dependent impacts on the performance of sequencing, batch effects, or a combination of these possibilities. This large discrepancy warrants further investigation and interpretation of findings at these CpG sites must be interpreted with caution. Discordant CpG sites between MC-seq and EPIC (difference>0.5) One of the limitations of this study is the small number of participants used to estimate inter-sample variability. A previous study used a benchmark approach to evaluate performance of different platforms [17] and concluded that the EPIC array performed better than the MC-seq platform. However, the study did not remove duplicate reads as part of their data processing, which may have compromised the QC for MC-seq data processing as discussed above. Future studies, including benchmarking using a larger sample size, could further improve the analysis of platform performance. Of note, MC-seq detected high percentages of CHG and CHH sites across four methylome, which is consistent with previous reports [15]. The significances of those methylation sites warrant further investigation. New approaches to measurement of DNA methylation continue to emerge that may warrant similar investigation in an ongoing effort to provide users with empiric comparisons to inform decisions about platform selection. One recent approach is enzymatic methyl-sequencing (EM-seq) (e.g., NEBNext EM-seq by New England Biolabs, Ipswich, MA) [22]. The input genomic DNA requirement is low 10–200 ng and EM-seq has comparable performance to WGBS [22], but its performance in relation to array- or capture sequencing-based approaches has not been reported. Should EM-seq gain popularity, it would be important to directly compare the performance of MC-seq and EM-seq to provide empiric evidence to users to inform platform selection. Nevertheless, we have demonstrated that MC-seq is an efficient, reliable, and affordable platform that allows medium input quantity of DNA input (i.e., > 300 ng), which is equivalent to DNA input required for EPIC array. MC-seq has the advantage of capturing significantly more CpG sites than the EPIC array. Although methylation measurements between the two platforms are highly consistent, we have identified a small number of CpG sites that must be interpreted with caution if they are associated with a trait of interest because they showed significant discrepancies between the two platforms.

Conclusions

Our results show that MC-seq is an efficient and reliable platform for methylome profiling with a broader coverage of the methylome than the array-based platform. Although methylation measurements in majority of CpGs are highly correlated, a number of CpG sites show large discrepancy between the two platforms, which warrants further investigation and needs cautious interpretation. Additional file 1: Figure S1. A Manhattan plot showing the distribution of Δβ between MC-seq and EPIC array in PBMC by chromosome positions. Blue line represents Δβ = 0.1 and red line represents Δβ = 0.5. Additional file 2: Table S1. Top 100 discordant CpG sites between MC-seq and EPIC array (Δβ = 0.1 ~ 0.4). Additional file 3: Figure S2. Comparison of methylation values measured by MC-seq and EPIC array among common CpG sites in participant S2, S3, and S4. Blue dots represent concordant CpGs with Δβ < 0.1 between the two platforms and green dots represent discordant quality with Δβ ≥ 0.1 Additional file 4: Figure S3. The density plot of methylation values among CpG sites assayed in common by MC-seq and EPIC array in participant S2, S3, and S4
  20 in total

Review 1.  Strategies for analyzing bisulfite sequencing data.

Authors:  Katarzyna Wreczycka; Alexander Gosdschan; Dilmurat Yusuf; Björn Grüning; Yassen Assenov; Altuna Akalin
Journal:  J Biotechnol       Date:  2017-08-16       Impact factor: 3.307

Review 2.  Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.

Authors:  Helai P Mohammad; Olena Barbash; Caretha L Creasy
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

Review 3.  Stress, burnout and depression: A systematic review on DNA methylation mechanisms.

Authors:  Jelena Bakusic; Wilmar Schaufeli; Stephan Claes; Lode Godderis
Journal:  J Psychosom Res       Date:  2016-11-23       Impact factor: 3.006

4.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications.

Authors:  Felix Krueger; Simon R Andrews
Journal:  Bioinformatics       Date:  2011-04-14       Impact factor: 6.937

5.  DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty.

Authors:  Xinyu Zhang; Ying Hu; Amy C Justice; Boyang Li; Zuoheng Wang; Hongyu Zhao; John H Krystal; Ke Xu
Journal:  Nat Commun       Date:  2017-12-21       Impact factor: 14.919

6.  DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development.

Authors:  Bon-Kyoung Koo; Matthias Zilbauer; Judith Kraiczy; Komal M Nayak; Kate J Howell; Alexander Ross; Jessica Forbester; Camilla Salvestrini; Roxana Mustata; Sally Perkins; Amanda Andersson-Rolf; Esther Leenen; Anke Liebert; Ludovic Vallier; Philip C Rosenstiel; Oliver Stegle; Gordon Dougan; Robert Heuschkel
Journal:  Gut       Date:  2017-11-15       Impact factor: 23.059

Review 7.  DNA methylation and cancer diagnosis.

Authors:  Yannick Delpu; Pierre Cordelier; William C Cho; Jérôme Torrisani
Journal:  Int J Mol Sci       Date:  2013-07-18       Impact factor: 5.923

8.  DNA methylation in peripheral tissue of schizophrenia and bipolar disorder: a systematic review.

Authors:  Nina Teroganova; Leah Girshkin; Catherine M Suter; Melissa J Green
Journal:  BMC Genet       Date:  2016-01-25       Impact factor: 2.797

9.  Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling.

Authors:  Ruth Pidsley; Elena Zotenko; Timothy J Peters; Mitchell G Lawrence; Gail P Risbridger; Peter Molloy; Susan Van Djik; Beverly Muhlhausler; Clare Stirzaker; Susan J Clark
Journal:  Genome Biol       Date:  2016-10-07       Impact factor: 13.583

Review 10.  Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis.

Authors:  Zhifu Sun; Julie Cunningham; Susan Slager; Jean-Pierre Kocher
Journal:  Epigenomics       Date:  2015-09-14       Impact factor: 4.778

View more
  6 in total

1.  Systematic evaluation of cell-type deconvolution pipelines for sequencing-based bulk DNA methylomes.

Authors:  Yunhee Jeong; Lisa Barros de Andrade E Sousa; Dominik Thalmeier; Reka Toth; Marlene Ganslmeier; Kersten Breuer; Christoph Plass; Pavlo Lutsik
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

2.  BiSulfite Bolt: A bisulfite sequencing analysis platform.

Authors:  Colin Farrell; Michael Thompson; Anela Tosevska; Adewale Oyetunde; Matteo Pellegrini
Journal:  Gigascience       Date:  2021-05-08       Impact factor: 6.524

3.  Epigenome-wide meta-analysis of PTSD symptom severity in three military cohorts implicates DNA methylation changes in genes involved in immune system and oxidative stress.

Authors:  Seyma Katrinli; Adam X Maihofer; Agaz H Wani; John R Pfeiffer; Elizabeth Ketema; Andrew Ratanatharathorn; Dewleen G Baker; Marco P Boks; Elbert Geuze; Ronald C Kessler; Victoria B Risbrough; Bart P F Rutten; Murray B Stein; Robert J Ursano; Eric Vermetten; Mark W Logue; Caroline M Nievergelt; Alicia K Smith; Monica Uddin
Journal:  Mol Psychiatry       Date:  2022-01-07       Impact factor: 13.437

4.  Extensive Placental Methylation Profiling in Normal Pregnancies.

Authors:  Ornella Rondinone; Alessio Murgia; Jole Costanza; Silvia Tabano; Margherita Camanni; Luigi Corsaro; Laura Fontana; Patrizia Colapietro; Luciano Calzari; Silvia Motta; Carlo Santaniello; Tatjana Radaelli; Enrico Ferrazzi; Silvano Bosari; Davide Gentilini; Silvia Maria Sirchia; Monica Miozzo
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 6.208

5.  Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer.

Authors:  Chi T Viet; Xinyu Zhang; Ke Xu; Gary Yu; Kesava Asam; Carissa M Thomas; Nicholas F Callahan; Coleen Doan; Paul C Walker; Khanh Nguyen; Stephanie C Kidd; Steve C Lee; Anupama Grandhi; Clint T Allen; Simon Young; James C Melville; Jonathan W Shum; Dan T Viet; Alan S Herford; Dylan F Roden; Manuel L Gonzalez; Jiang F Zhong; Bradley E Aouizerat
Journal:  Biomark Res       Date:  2021-12-20

6.  Identification of influential probe types in epigenetic predictions of human traits: implications for microarray design.

Authors:  Robert F Hillary; Daniel L McCartney; Allan F McRae; Archie Campbell; Rosie M Walker; Caroline Hayward; Steve Horvath; David J Porteous; Kathryn L Evans; Riccardo E Marioni
Journal:  Clin Epigenetics       Date:  2022-08-10       Impact factor: 7.259

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.